Expected Platelet Increment After Transfusion
One unit of whole blood-derived platelet concentrate should increase the platelet count by approximately 5,000-10,000/μL (5-10 × 10⁹/L) in a 70 kg adult, while one apheresis unit should increase the count by approximately 30,000-50,000/μL (30-50 × 10⁹/L). 1
Standard Dosing and Expected Increments
Whole Blood-Derived Platelet Concentrates
- Each unit contains approximately 0.7-0.75 × 10¹¹ platelets on average 1
- Expected increment: 5,000-10,000/μL per unit in a 70 kg recipient 1
- For average-sized adults, a rough estimate is 2,000/μL per unit of platelet concentrate 1
Apheresis Platelet Units
- Contains approximately 3-6 × 10¹¹ platelets (equivalent to 4-8 whole blood-derived units) 1
- Expected increment: 30,000-50,000/μL (or approximately 10,000/μL per apheresis unit) 1
- A pool of 4-8 platelet concentrates or a single-donor apheresis unit is usually sufficient to provide hemostasis in a thrombocytopenic, bleeding patient 1
Calculating Expected Increments: The Corrected Count Increment (CCI)
The American Society of Clinical Oncology endorses using the CCI to assess transfusion adequacy 1:
CCI Formula:
- CCI = (absolute increment × body surface area in m²) / (number of platelets transfused × 10¹¹) 1
- A CCI ≥ 5,000 defines a satisfactory response 1
Practical Simplified Approach
Since most centers don't routinely provide platelet counts of infused products, the ASCO guidelines suggest 1:
- Adults: Expect approximately 2,000/μL increment per unit of platelet concentrate (assuming average body surface area of 1.76 m² and 0.7 × 10¹¹ platelets per unit) 1
- Children: Expect approximately 3,500/m²/unit 1
Timing of Post-Transfusion Assessment
- Measure platelet count 10-60 minutes (or 1 hour) after transfusion completion to assess immediate increment 1
- A 10-minute post-transfusion count yields identical results to a 1-hour count and is practical since the patient must be seen when the transfusion is completed 1
Clinical Factors That Reduce Expected Increments
Several conditions can significantly diminish the expected platelet increment 1:
Non-Immune Factors
- Sepsis and active infection 1
- Splenomegaly (approximately 33% of transfused platelets pool in the spleen normally) 1
- Disseminated intravascular coagulation (DIC) 1
- Massive hemorrhage 1
- Amphotericin B plus antibiotic therapy 2
- Graft-versus-host disease 2
Immune Factors
- Alloimmunization (HLA antibodies in approximately 90% of cases) 1
- ABO incompatibility can compromise post-transfusion increments 1
Product-Related Factors
- Platelet storage time (use platelets stored <72 hours when assessing refractoriness) 1
- Leukofiltration may result in some platelet loss 2
Special Populations
Trauma Patients
- In trauma with massive transfusion, one standard adult platelet dose may increase count by only 5-10 × 10⁹/L 1
- The platelet concentrate must be ABO-identical or at least ABO-compatible to provide good yield 1
Cirrhosis Patients
- Transfusion of one standard adult platelet dose produces only a small increase in platelet count 1, 3
- In one study, platelet count increased from 39 × 10⁹/L to only 52 × 10⁹/L after one standard dose 1, 3
- Post-transfusion counts often remain below 100 × 10⁹/L, the threshold where thrombin generation normalizes 3
Defining Platelet Refractoriness
Refractoriness should only be diagnosed when at least two consecutive ABO-compatible transfusions (stored <72 hours) result in poor increments 1:
This conservative definition is critical because patients may have a poor increment to a single transfusion yet have adequate increments with subsequent transfusions 1.
Common Pitfalls to Avoid
- Don't diagnose refractoriness based on a single poor increment – at least two consecutive poor responses are required 1
- Don't use ABO-incompatible platelets when assessing refractoriness – this can artificially lower increments 1
- Don't rely solely on platelet count – in trauma and critical illness, platelet dysfunction may occur despite normal counts 4
- Don't assume one standard dose is sufficient in all patients – larger patients or those with clinical complications may require higher doses 2